Clinical Trial Update: An Observational Study to Evaluate Tolerability of PREZISTA or INTELENCE in HIV-1 Infected Patients

View source ↗

Summary

This is a completed observational study evaluating the tolerability of PREZISTA (darunavir) or INTELENCE (etravirine) in HIV-1–infected patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Intelence (Etravirine)
• PREZISTA (darunavir)

Snippet

Sponsor: Janssen Inc. | Conditions: Human Immunodeficiency Virus (HIV) | Status: COMPLETED